Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. is a late clinical-stage biotechnology company focused on pioneering cell therapy for autoimmune diseases. The company utilizes its proprietary technology and manufacturing platform to introduce messenger RNA (mRNA) into cells to achieve a therapeutic effect in patients with various autoimmune conditions. This approach differs from DNA-based therapies as mRNA naturally degrades over time without integrating into the cell's genetic material. Cartesian Therapeutics' cell therapies are designed for repeated dosing, outpatient administration, and do not require pre-treatment chemotherapy, which is often necessary with many conventional cell therapies. Autoimmune diseases encompass over 80 disorders where the immune system mistakenly attacks the body. On November 13, 2023, the company, formerly known as Selecta Biosciences, Inc., completed a merger with Cartesian Therapeutics, Inc. (Old Cartesian), a Delaware corporation, and subsequently changed its corporate name to Cartesian Therapeutics, Inc.